MyMD Pharmaceuticals (NASDAQ:MYMD) and Ipsen (OTCMKTS:IPSEY) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, risk and valuation.
Institutional & Insider Ownership
13.1% of MyMD Pharmaceuticals shares are held by institutional investors. 0.3% of MyMD Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This table compares MyMD Pharmaceuticals and Ipsen’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|MyMD Pharmaceuticals||$1.58 million||184.26||-$17.58 million||N/A||N/A|
|Ipsen||$3.07 billion||2.76||$625.98 million||$2.09||12.10|
Ipsen has higher revenue and earnings than MyMD Pharmaceuticals.
Risk and Volatility
MyMD Pharmaceuticals has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, Ipsen has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500.
This is a breakdown of current ratings and target prices for MyMD Pharmaceuticals and Ipsen, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares MyMD Pharmaceuticals and Ipsen’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Ipsen beats MyMD Pharmaceuticals on 6 of the 9 factors compared between the two stocks.
About MyMD Pharmaceuticals
MyMD Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the development of drug products in the targeting of aging and age-related diseases; autoimmune diseases; and chronic pain, anxiety, and sleep disorders. It commercializes MYMD-1, a novel therapeutic to impact conditions related to immunometabolic dysregulation; and SUPERA-1R, a synthetic cannabidiol that offers bioavailability and potency than botanicals. The company was incorporated in 2014 and is based in Tampa, Florida.
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience and rare diseases. It operates through following segments: Specialty Care and Consumer Healthcare. The Specialty Care segment focuses on Oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and Rare Diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The Consumer Healthcare segment include brands such as Smecta, a naturally extracted purified clay for the symptomatic treatment of acute diarrhea; Tanakan, a standardized extract from the leaves of Ginkgo biloba for the treatment of various neurological and neuro-sens or ial disorders; Forlax, an osmotic laxative indicated for the symptomatic treatment of constipation in adults an
Receive News & Ratings for MyMD Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyMD Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.